Patents by Inventor Edwin A. Peets

Edwin A. Peets has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
    Patent number: 5256410
    Abstract: Human squamous cell carcinoma is successfully treated by intralesional administration of recombinant human interferon alpha-2b.
    Type: Grant
    Filed: May 20, 1991
    Date of Patent: October 26, 1993
    Assignee: Schering Corporation
    Inventors: Daniel J. Tanner, Edwin A. Peets, Kenneth A. Smiles
  • Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
    Patent number: 5028422
    Abstract: This invention relates to a method of treating basal cell carcinoma with purified human recombinant DNA interferon alpha-2, preferably purified human recombinant DNA interferon alpha-2b by administering intralesionally (by injection) to a patient in need of such treatment, a sufficient amount of the purified human recombinant DNA alpha interferon, preferably recombinant DNA interferon alpha-2b, to be effective as an antitumor agent.
    Type: Grant
    Filed: April 13, 1989
    Date of Patent: July 2, 1991
    Assignee: Schering Corporation
    Inventors: Daniel J. Tanner, Edwin A. Peets, Kenneth A. Smiles
  • Treatment of actinic keratoses with alpha.sub.2 interferon
    Patent number: 5002764
    Abstract: A method of treating actinic keratoses with alpha.sub.2 interferon is disclosed.
    Type: Grant
    Filed: August 22, 1989
    Date of Patent: March 26, 1991
    Assignee: Schering Corporation
    Inventors: Edwin A. Peets, Kenneth A. Smiles, Daniel J. Tanner
  • Treatment of genital warts with a combination of liquid nitrogen and recombinant DNA human alpha interferon
    Patent number: 4959210
    Abstract: Condylomata Acuminata infections (anogenital warts) are treated in infected patients by administering liquid nitrogen and immediately thereafter beginning administering recombinant DNA human alpha interferon thrice a week for three weeks.The interferon exemplified is recombinant DNA human interferon alfa-2b in which 1.0.times.10.sup.6 International Units are administered by injection to each lesion.The liquid nitrogen is the cryosurgical agent exemplified and it is topically administered to each lesion by conventional means.
    Type: Grant
    Filed: November 1, 1988
    Date of Patent: September 25, 1990
    Assignee: Schering Corporation
    Inventors: Kenneth A. Smiles, Edwin A. Peets, Daniel J. Tanner
  • Triazolo [4,5-d]-pyrimidines
    Patent number: 4076711
    Abstract: This disclosure relates to the method for the treatment of psoriasis which comprises the topical administration to a mammal suffering from psoriasis of an effective dose for treating psoriasis of a 7X-5Q-3Y-3H-.gamma.-triazolo[4,5-d]-pyrimidine wherein X is halogeno, alkoxy, or --NRR.sub.1, R and R.sub.1 being lower alkyl, Y is cycloalkyl, hydroxycycloalkyl, phenyl, bicycloalkyl, or A--R.sub.2 with A being methylene or ethylene and R.sub.2 being phenyl or bicycloalkyl, and Q is hydrogen or Y.
    Type: Grant
    Filed: December 22, 1976
    Date of Patent: February 28, 1978
    Assignee: Schering Corporation
    Inventors: Ashit K. Ganguly, Edwin A. Peets, Anil K. Saksena